通过DNA编码图书馆技术发现了第一个选择性的小分子GFRα2/3抑制剂
Shea L Johnson1, Galen Missig1, Minghua Wang1
1Cerevel Therapeutics, 222 Jacobs St., Cambridge, MA 02141, United States.
Bioorganic & medicinal chemistry letters
|July 14, 2024
概括
研究人员发现了一种针对GFRα-RET通路的新型小分子抑制剂,为疼痛和状况提供了一种新的治疗方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 破坏联体-RET-GFRα复合体是治疗疼痛和的潜在策略.
- 用DNA编码的图书馆 (DELs) 在药物发现中有效地识别了命中标识.
研究的目的:
- 利用DEL技术识别GFRα-RET接口的小分子抑制剂.
- 在RET上发现GFRα2和GFRα3的选择性抑制剂.
主要方法:
- 使用DNA编码库 (DEL) 进行高通量选.
- 化合物16的特征是其抑制活性和选择性.
主要成果:
- 化合物16被确定为第一个GFRα2/GFRα3.3的小分子抑制剂.
- 化合物16的抑制度为GFRα2的0.1μM和GFRα3.3的0.2μM.
- 该化合物表现出对RET的选择性.
结论:
- 化合物16是开发针对GFRα-RET接口的新疗法的一个有前途的头.
- 这一发现通过抑制GFRα-RET通路,为治疗疼痛和开辟了新的途径.
更多相关视频
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
7.7K
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
6.9K
相关概念视频
Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
